ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Pulmonary Disease

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

11,110Medicare Part D Prescriptions Filled, Including Refills

Rank: 2 out of 31

$699K Total Retail Price of All Prescriptions

Rank: 8 out of 31

635 Patients Receiving at Least One Drug in Part D
86%Patients 65 Years and Older
18% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Rhode Island
Lower avg

Schedule Two
Controlled Substances

3% of this provider’s 635 patients filled at least one prescription for a schedule two drug, compared to an average of 1%.

Schedule Three
Controlled Substances

5% of this provider’s 635 patients filled at least one prescription for a schedule three drug, compared to an average of 1%.

Risky Drugs to Seniors

1% of this provider’s 9,751 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 0%.

Brand Name Drugs

31% of this provider’s prescriptions were for brand-name drugs, compared to an average of 58%.

Prescription Price

$63 was the average price of a prescription from this provider, compared to $140 among peers.

Prescriptions per Patient

18 is the average number of prescriptions (including refills) per patient, compared to an average of 11.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Rhode Island
SIMVASTATIN 526 443 1 14
LISINOPRIL 488 411 2 8
HYDROCHLOROTHIAZIDE 421 397 3 13
PROAIR HFA 421 365 3 3
ADVAIR DISKUS 359 308 5 2
OMEPRAZOLE 345 269 6 6
LEVOTHYROXINE SODIUM 325 304 7 15
AMLODIPINE BESYLATE 278 267 8 11
FUROSEMIDE 276 229 9 12
ATENOLOL 269 269 10 23
CITALOPRAM HBR 233 191 11 34
SYMBICORT 215 194 12 5
PREDNISONE 200 188 13 4
LOSARTAN POTASSIUM 195 182 14 22
ATORVASTATIN CALCIUM 193 179 15 18
FLUTICASONE PROPIONATE 185 172 16 9
SPIRIVA 179 157 17 1
METOPROLOL TARTRATE 165 149 18 17
SERTRALINE HCL 157 144 19 32
ZOLPIDEM TARTRATE 141 132 20 20
RANITIDINE HCL 128 125 21 41
PRAVASTATIN SODIUM 124 122 22 25
LOVASTATIN 124 124 22 30
SYNTHROID 121 105 24 48
TAMSULOSIN HCL 120 110 25 58
HYDROCODONE-ACETAMINOPHEN 119 75 S3 26 24
METFORMIN HCL 108 101 27 27
LIPITOR 107 99 28 40
ALLOPURINOL 103 103 29 43
AZITHROMYCIN 100 89 30 16
ALENDRONATE SODIUM 96 96 31 39
NEXIUM 92 84 32 62
TRAZODONE HCL 89 71 33 36
SINGULAIR 88 84 34 7
GLYBURIDE 81 81 R 35 73
VENTOLIN HFA 81 76 35 29
DIOVAN 79 65 37 33
DONEPEZIL HCL 78 78 38 74
OXYCODONE HCL 68 67 S2 39 50
PANTOPRAZOLE SODIUM 68 43 39 38
ZETIA 68 58 39 83
MONTELUKAST SODIUM 65 57 42 21
WARFARIN SODIUM 64 47 43 35
CLOPIDOGREL 64 64 43 51
OXYCODONE-ACETAMINOPHEN 61 33 S2 45 92
COMBIVENT 60 59 46 10
METOPROLOL SUCCINATE 59 59 47 37
GABAPENTIN 59 55 47 42
BISOPROLOL FUMARATE 57 57 49 53
FLUOXETINE HCL 55 45 50 63
MELOXICAM 54 43 51 97
CIPROFLOXACIN HCL 53 40 52 56
PAROXETINE HCL 50 34 53 68
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Feb. 2, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.